Impact of Maternal Body Mass Index on Infant Hypoxic Events at Time of Delivery ,Cross-sectional Study.

Offspring from overweight or obese mothers appear to be at up to 38% increased risk of being admitted to the neonatal intensive care unit than the offspring of mothers with a normal BMI. In terms of Apgar scores at birth, babies of obese mothers have been reported to have a 31% excess risk of having a low Apgar score (defined at <7 at 1 minute) . Infants born to obese mothers demonstrate a spectrum of outcomes, suggesting that there is a complex interplay of factors that defines the precise altered metabolic environment to which the fetus is exposed and that determines the risk of complications

Study Overview

• Status: Not yet recruiting
• Conditions: Maternal Obesity; Hypoxia Neonatal
• Intervention / Treatment: Other: compare infant hypoxic events in both groups

Detailed Description

The investigators need to improve understanding of the specific molecular factors that contribute either individually or synergistically to detrimental fetal outcomes. Moreover, The investigators need to identify the essential maternal markers that need to be tightly regulated during pregnancy to improve outcomes. Here in, The investigators discuss the influence of maternal obesity and factors associated with the obesogenic intrauterine environment on fetal lung development and respiratory outcomes in offspring at birth importantly, The investigators identify a series of molecular changes encountered during pregnancy that may program the observed respiratory outcomes in clinical practice. The effects of maternal obesity on severe neonatal asphyxia may be partly explained by traumatic labor, which often results from macrosomia. Another consequence of maternal obesity is fetal hyperinsulinemia, which may be related to chronic hypoxia even without diabetes . Other mechanisms that explain the effect of maternal obesity on neonatal asphyxia include lipotoxicity, placental inflammation and vasculopathy, and cord coiling. Evidence has demonstrated altered gene expression in full-term newborns of mothers with obesity, involving dysregulation of brain development, inflammatory and immune signaling, glucose and lipid homeostasis, and oxidative stress

• Study Type: Observational
• Enrollment (Estimated): 544

Contacts and Locations

• Study Contact: Name: Esraa Hussein, master; Phone Number: 01008057054; Email: esraaghoneimy81@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

18 - 40 years pregnant females 37 weeks or more

Description

Inclusion Criteria:

1. Age of 18 - 40 years.
2. Term pregnancy (37 weeks gestation or more)
3. Singleton pregnancy
4. Cephalic presentation at time of delivery
5. In labour

Exclusion Criteria:

1. Any medical disorders that affect neonatal outcomes (diabetes mellitus, hypertension, mixed connective tissue disorders)
2. Scarred uterus (myomectomy, previous cesarean section)
3. Macrosomic baby>4 kgs
4. Condition jeopardizing the maternal or fetal life (for example: antepartum hemorrhage, pathological CTG, cord prolapse)
5. Liquor abnormalities (oligohydramnios or polyhydramnios).
6. Other indications for cesarean sections for example: placenta accreta spectrum
7. Smokers.
8. Any abnormalities in follow up of delivery regarding partogram.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
group A (case group ); women with body mass index equal to 25 kg/m2 or more at time of delivery.	Other: compare infant hypoxic events in both groups; early neonatal resuscitation will be done by the pediatrician according to the guidelines, APGAR score of the baby will be calculated,, any hypoxic events will be traced and any need of respiratory support for the baby or NICU admission, as well as weight of the baby, mode of delivery and any birth traumas will be recorded.all this will be compared between two groups.
group B ( control group ); women with body mass index (18.5-24.9 kg/m2) at time of delivery	Other: compare infant hypoxic events in both groups; early neonatal resuscitation will be done by the pediatrician according to the guidelines, APGAR score of the baby will be calculated,, any hypoxic events will be traced and any need of respiratory support for the baby or NICU admission, as well as weight of the baby, mode of delivery and any birth traumas will be recorded.all this will be compared between two groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Rate of admission to neonatal observation room	6 hours post delivery

Secondary Outcome Measures

Outcome Measure	Time Frame
Rate of cesarean-sections.	12 hours
Oxygen saturation at birth.	2 hours post delivery
Number of babies with NICU Admission.	6 hours post delivery
Number of babies with birth trauma.	2 hours post delivery
Number of babies with meconium aspiration.	2 hours post delivery

Collaborators and Investigators

• Sponsor: Ain Shams University

Study record dates

Study Major Dates

• Study Start (Estimated): April 20, 2025
• Primary Completion (Estimated): January 28, 2026
• Study Completion (Estimated): January 28, 2026

Study Registration Dates

• First Submitted: March 6, 2025
• First Submitted That Met QC Criteria: April 4, 2025
• First Posted (Actual): April 9, 2025

Study Record Updates

• Last Update Posted (Actual): April 9, 2025
• Last Update Submitted That Met QC Criteria: April 4, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: maternal obesity; hypoxia neonatal
• Additional Relevant MeSH Terms: Urogenital Diseases; Nutrition Disorders; Female Urogenital Diseases and Pregnancy Complications; Overnutrition; Body Weight; Pregnancy Complications; Signs and Symptoms, Respiratory; Overweight; Obesity; Obesity, Maternal; Hypoxia
• Other Study ID Numbers: MD344/2024

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No